Retrospective analysis of KRAS status in metastatic colorectal cancer patients: A single-center feasibility study

Clinical and Experimental Gastroenterology

Volumn 5, Issue 1, 2012, Pages 167-171

  Montomoli, Jonathan ^a   Jacques, Stephen ^a   Hamilton Dutoit, ^a   Frøslev, Trine ^a   Taylor, Aliki ^b   Erichsen, Rune ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AMGEN LTD   (United Kingdom)

Author keywords

Colorectal neoplasms; Feasibility study; KRAS; Registries; Survival

Indexed keywords

K RAS PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 84866772324     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S34725     Document Type: Article

References (30)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765-781.
2. Henry KA, Niu X, Boscoe FP. Geographic disparities in colorectal cancer survival. Int J Health Geogr. 2009;8:48.
3. Genovesi D, Cefaro GA, Vinciguerra A, et al. Retrospective long-term results and prognostic factors of postoperative treatment for UICC stages II and III rectal cancer. Tumori. 2009;95(6):675-682.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
5. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15(7):699-731.
6. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154(1):37-49.
7. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20): 2040-2048.
8. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25(13):1658-1664.
9. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005;1756(2):81-82.
10. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3(11):e3698.
11. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005;129(3):837-845.
12. Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287(5462):2398-2399.
13. College of American Pathologists. Systematized Nomenclature of Medicine. 2nd ed. Chicago: College of American Pathologists; 1979.
14. Vyberg M, Bjerregaard B, Bak M, Gram I, Hvolris H. Pathology database. Danish Society of Pathologic Anatomy and Cytology. Ugeskr Laeger. 2005;167(12-13):1401. Danish.
15. Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010; 2:51-56.
16. DxS-Cancer Mutation Products-Europe-TheraScreen K-RAS. Available from: http://www.qiagen.com/products/therascreenkrasrgqpcrkit.aspx#Tabs=t1. Accessed September 10, 2012.
17. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268.
18. Hermsen M, Postma C, Baak J, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology. 2002;123(4):1109-1119.
19. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283-1286.
20. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104(6):1020-1026.
21. Deschoolmeester V, Boeckx C, Baay M, et al. KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. Br J Cancer. 2010;103(10):1627-1636.
22. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17(2):572-578.
23. Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004; 91(2):355-358.
24. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17(5):1122-1130.
25. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304(16):1812-1820.
26. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27(5):663-671.
27. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull. 1997;44(5): 535-539.
28. Nickelsen TN, Harling H, Kronborg O, Bulow S, Jorgensen T. The completeness and quality of the Danish Colorectal Cancer clinical database on colorectal cancer. Ugeskr Laeger. 2004;166(36):3092-3095.
29. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer. 2010;102(4):693-703.
30. Jensen LH, Kuramochi H, Cruger DG, et al. Gene expression of the mismatch repair gene MSH2in primary colorectal cancer. Tumour Biol. 2011;32(5):977-983.